Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.
Data-Driven Decision-Making in Advanced Breast Cancer: HER2 and HER2-low Breast Cancer Updates
Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.
Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.
Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.
Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5